Compare · ARGX vs GLUE
ARGX vs GLUE
Side-by-side comparison of argenx SE (ARGX) and Monte Rosa Therapeutics Inc. (GLUE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and GLUE operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $16.17B, about 32.4x GLUE ($499.0M).
- GLUE has been more active in the news (6 items in the past 4 weeks vs 2 for ARGX).
- ARGX has more recent analyst coverage (25 ratings vs 11 for GLUE).
- Company
- argenx SE
- Monte Rosa Therapeutics Inc.
- Price
- $780.08-1.00%
- $19.79-1.98%
- Market cap
- $16.17B
- $499.0M
- 1M return
- +11.90%
- -
- 1Y return
- +25.72%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2021
- News (4w)
- 2
- 6
- Recent ratings
- 25
- 11
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ARGX
- SEC Form 6-K filed by argenx SE
- argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP
- SEC Form 6-K filed by argenx SE
- argenx announces Annual General Meeting of Shareholders on May 6, 2026
- SEC Form 20-F filed by argenx SE
- SEC Form 6-K filed by argenx SE
- argenx upgraded by Deutsche Bank
- SEC Form 6-K filed by argenx SE
- argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline
- SEC Form 6-K filed by argenx SE
Latest GLUE
- Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors
- SEC Form 144 filed by Monte Rosa Therapeutics Inc.
- SEC Form 4 filed by Warmuth Markus
- SEC Form 4 filed by Nickson Philip
- SEC Form 4 filed by Bowen Matthew
- SEC Form 3 filed by new insider Bowen Matthew
- Amendment: SEC Form SCHEDULE 13D/A filed by Monte Rosa Therapeutics Inc.
- SEC Form S-8 filed by Monte Rosa Therapeutics Inc.
- SEC Form 10-K filed by Monte Rosa Therapeutics Inc.
- Monte Rosa Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits